NASDAQ:AMRX - Nasdaq - US03168L1052 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to AMRX. AMRX was compared to 193 industry peers in the Pharmaceuticals industry. While AMRX is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -0.39% | ||
ROE | N/A | ||
ROIC | 11.15% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 12.87% | ||
PM (TTM) | N/A | ||
GM | 36.69% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | 1.56 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.4 | ||
Quick Ratio | 0.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 12.76 | ||
Fwd PE | 9.83 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 8.04 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:AMRX (7/15/2025, 12:56:17 PM)
8.295
-0.12 (-1.48%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 12.76 | ||
Fwd PE | 9.83 | ||
P/S | 0.92 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | 8.04 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -0.39% | ||
ROE | N/A | ||
ROCE | 15.91% | ||
ROIC | 11.15% | ||
ROICexc | 11.42% | ||
ROICexgc | 23.32% | ||
OM | 12.87% | ||
PM (TTM) | N/A | ||
GM | 36.69% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 4.16 | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.4 | ||
Quick Ratio | 0.84 | ||
Altman-Z | 1.56 |